These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 9877235)

  • 1. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer.
    Hoff PM; Pazdur R
    Oncologist; 1998; 3(3):155-164. PubMed ID: 10388099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Noel D; Sonnichsen DS; Birkhofer MJ
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):22-5. PubMed ID: 9348562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
    Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Bin Q; Li J; Liao C; Cao Y; Gao F
    Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UFT in the treatment of colorectal and breast cancer.
    Sun W; Haller D
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for phase I study of UFT plus leucovorin and oral JM-216.
    DeMario MD; Ratain MJ
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):26-9. PubMed ID: 9348563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer.
    Diaz-Canton E; Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):58-60. PubMed ID: 9348571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
    Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of UFT in metastatic colorectal cancer.
    Bennouna J; Saunders M; Douillard JY
    Oncology; 2009; 76(5):301-10. PubMed ID: 19299903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I
    Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.